文献速递心脑血管急症重症综合管理与镇静镇痛

甲泼尼龙作为血管内取栓辅助治疗大血管闭塞性卒中:MARVEL随机临床试验

Methylprednisolone as Adjunct to Endovascular Thrombectomy for Large-Vessel Occlusion Stroke: The MARVEL Randomized Clinical Trial.
PubMed 文献 · JAMA · 2024-01-01
一句话结论在因大血管闭塞接受血管内取栓的急性缺血性卒中患者中,辅助静脉甲泼尼龙2 mg/kg/d连用3天未显著改善90天整体残疾程度(校正广义OR 1.10,95%CI 0.96-1.25;P=0.17)。

MARVEL试验为研究者发起、随机、双盲、安慰剂对照试验,在中国82家医院纳入1680例发病24小时内的前循环大血管闭塞性卒中患者,随机接受静脉甲泼尼龙2 mg/kg/d或安慰剂治疗3天,均辅助血管内取栓。主要疗效终点90天改良Rankin量表整体分布无显著差异(校正广义OR 1.10,95%CI 0.96-1.25;P=0.17)。甲泼尼龙组90天死亡率(23.2% vs 28.5%;校正RR 0.84,95%CI 0.71-0.98;P=0.03)和48小时内症状性颅内出血发生率(8.6% vs 11.7%;校正RR 0.74,95%CI 0.55-0.99;P=0.04)均低于安慰剂组。结论认为辅助甲泼尼龙未显著改善整体残疾程度。

要点

  • 因大血管闭塞接受血管内取栓的急性缺血性卒中患者,辅助静脉甲泼尼龙2 mg/kg/d连用3天未显著改善90天整体残疾程度(校正广义OR 1.10,95%CI 0.96-1.25;P=0.17)。
  • 甲泼尼龙组90天死亡率23.2% vs 安慰剂组28.5%(校正RR 0.84,95%CI 0.71-0.98;P=0.03)。
  • 甲泼尼龙组48小时内症状性颅内出血发生率8.6% vs 安慰剂组11.7%(校正RR 0.74,95%CI 0.55-0.99;P=0.04)。
  • 该试验在中国82家医院纳入1680例发病24小时内的前循环大血管闭塞性卒中患者,1673例(99.6%)完成试验。

适用人群与场景

  • 发病24小时内(最后已知正常时间起)的前循环大血管闭塞性急性缺血性卒中患者,接受血管内取栓治疗。

处置流程与药物剂量

  • 静脉甲泼尼龙2 mg/kg/d,连用3天,辅助血管内取栓;安慰剂组对应使用安慰剂。

研究设计与关键结果

  • 研究类型:研究者发起、随机、双盲、安慰剂对照试验,在中国82家医院开展,纳入1680例患者(甲泼尼龙组839例,安慰剂组841例),中位年龄69岁,女性727例(43.3%),1673例(99.6%)完成试验。
  • 主要疗效终点:90天改良Rankin量表评分整体分布,甲泼尼龙组中位3分(IQR 1-5)vs 安慰剂组3分(IQR 1-6),校正广义OR 1.10(95%CI 0.96-1.25;P=0.17)。
  • 主要安全终点:90天死亡率甲泼尼龙组23.2% vs 安慰剂组28.5%(校正RR 0.84,95%CI 0.71-0.98;P=0.03);48小时内症状性颅内出血发生率甲泼尼龙组8.6% vs 安慰剂组11.7%(校正RR 0.74,95%CI 0.55-0.99;P=0.04)。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照试验(MARVEL)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于因大血管闭塞接受血管内取栓的急性缺血性卒中患者,作者认为辅助甲泼尼龙未显著改善整体残疾程度,但观察到90天死亡率和48小时内症状性颅内出血发生率降低。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: It is uncertain whether intravenous methylprednisolone improves outcomes for patients with acute ischemic stroke due to large-vessel occlusion (LVO) undergoing endovascular thrombectomy.

OBJECTIVE: To assess the efficacy and adverse events of adjunctive intravenous low-dose methylprednisolone to endovascular thrombectomy for acute ischemic stroke secondary to LVO.

DESIGN, SETTING, AND PARTICIPANTS: This investigator-initiated, randomized, double-blind, placebo-controlled trial was implemented at 82 hospitals in China, enrolling 1680 patients with stroke and proximal intracranial LVO presenting within 24 hours of time last known to be well. Recruitment took place between February 9, 2022, and June 30, 2023, with a final follow-up on September 30, 2023.

INTERVENTIONS: Eligible patients were randomly assigned to intravenous methylprednisolone (n = 839) at 2 mg/kg/d or placebo (n = 841) for 3 days adjunctive to endovascular thrombectomy.

MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was disability level at 90 days as measured by the overall distribution of the modified Rankin Scale scores (range, 0 [no symptoms] to 6 [death]). The primary safety outcomes included mortality at 90 days and the incidence of symptomatic intracranial hemorrhage within 48 hours.

RESULTS: Among 1680 patients randomized (median age, 69 years; 727 female [43.3%]), 1673 (99.6%) completed the trial. The median 90-day modified Rankin Scale score was 3 (IQR, 1-5) in the methylprednisolone group vs 3 (IQR, 1-6) in the placebo group (adjusted generalized odds ratio for a lower level of disability, 1.10 [95% CI, 0.96-1.25]; P = .17). In the methylprednisolone group, there was a lower mortality rate (23.2% vs 28.5%; adjusted risk ratio, 0.84 [95% CI, 0.71-0.98]; P = .03) and a lower rate of symptomatic intracranial hemorrhage (8.6% vs 11.7%; adjusted risk ratio, 0.74 [95% CI, 0.55-0.99]; P = .04) compared with placebo.

CONCLUSIONS AND RELEVANCE: Among patients with acute ischemic stroke due to LVO undergoing endovascular thrombectomy, adjunctive methylprednisolone added to endovascular thrombectomy did not significantly improve the degree of overall disability.

TRIAL REGISTRATION: ChiCTR.org.cn Identifier: ChiCTR2100051729.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Yang Q, Guo C, Yue C, et al. Methylprednisolone as Adjunct to Endovascular Thrombectomy for Large-Vessel Occlusion Stroke: The MARVEL Randomized Clinical Trial. JAMA. 2024. PMID: 38329440. doi:10.1001/jama.2024.0626

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。